C型肝炎ウイルス：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Drivers and Barriers – Global Issues 16
4 Current and Future Players 21
4.1 Overview 21
4.2 Trends in Corporate Strategy 23
4.3 Company Profiles 24
4.3.1 Merck 24
4.3.2 Roche 26
4.3.3 Vertex 28
4.3.4 Janssen 29
4.3.5 Gilead 31
4.3.6 AbbVie 34
4.3.7 Bristol-Myers Squibb 36
4.3.8 Boehringer Ingelheim 38
4.4 Additional Companies with Promising Drugs 40
4.4.1 Mitsubishi Tanabe 40
4.4.2 GlaxoSmithKline 41
4.4.3 Achillion 41
4.4.4 Scynexis 42
4.4.5 Idenix 43
4.4.6 Presidio 44
5 Appendix 45
5.1 Bibliography 45
5.2 Abbreviations 48
5.3 Methodology 49
5.4 Forecasting Methodology 49
5.4.1 Percent Drug-Treated Patients 49
5.4.2 Patient Warehousing 50
5.4.3 Drugs Included in Each Therapeutic Class 50
5.4.4 Launch and Patent Expiry Dates 51
5.4.5 General Pricing Assumptions 52
5.4.6 Individual Drug Assumptions 52
5.4.7 Generic Erosion 55
5.4.8 Selection of Pipeline Agents 55
5.4.9 Pricing of Pipeline Agents 56
5.5 Physicians and Specialists Included in this Study 59
5.6 Survey of Prescribing Physicians 61
5.7 About the Authors 62
5.7.1 Author 62
5.7.2 Epidemiologist 62
5.7.3 Global Head of Healthcare 63
5.8 About GlobalData 64
5.9 Contact Us 64
5.10 Disclaimer 64